Cite
HARVARD Citation
Flume, P. et al. (2021). Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Lancet. 9 (7), pp. 733-746. [Online].